Peripheral cryobiopsy for solitary pulmonary nodules

1.1 mm flexible single-use cryoprobe for the diagnosis of sub-solid lesions

**Background**

Solitary pulmonary nodules (SPNs) are referred to as radiological appearances which can harbor a primary lung malignancy, distant metastasis or benign conditions (e.g. infectious, congenital)\(^1\). SPNs are divided into solid and sub-solid lesions. Ground-glass opacity lesions (GGOs) are a subgroup of sub-solid lesions.

A valid diagnosis of SPNs by tissue examination is important to define the further management of the patient.

In their present retrospective, single-center trial *A pilot study of the ultrathin cryoprobe in the diagnosis of peripheral pulmonary ground-glass opacity lesions*, Jiang et al. from Shanghai Chest Hospital evaluated 20 consecutive patients undergoing peripheral cryobiopsy for GGOs with the 1.1 mm flexible single-use cryoprobe\(^2\).

**Challenges and goals**

Ground-glass opacity lesions (GGOs) represent a subgroup of sub-solid lesions, which are characterized by an increased opacity of lung tissue on high-resolution computed tomography\(^1,2\).

Different techniques have been described in the literature for biopsy of peripheral lesions (transthoracic needle aspiration, transbronchial forceps biopsy or cryobiopsy and surgical lung biopsy). Using interventional pulmonological procedures, GGOs can be harder to diagnose compared to solid lesions\(^2\).

Jiang et al. conducted the first study evaluating the clinical use of the 1.1 mm flexible single-use cryoprobe on peripheral cryobiopsy specifically for the diagnosis of GGOs\(^2\).
Method

At Shanghai Chest Hospital, 20 consecutive patients with 23 GGOs underwent peripheral cryobiopsy. The diagnostic yield was defined as the rate of correct diagnoses taking into account a comprehensive analysis of histology, microbiology and clinical follow-up.

Before bronchoscopy, high-resolution computed tomography was used to evaluate the GGO. During bronchoscopy, virtual bronchoscopic navigation and endobronchial ultrasound were applied for localisation of the lesion.

Implications

Although all lesions showed risk factors for transbronchial interventions resulting in a poor diagnostic yield, Jiang et al. demonstrated high diagnostic efficacy, feasibility and safety in sampling GGOs with the 1.1 mm flexible single-use cryoprobe.

Bending into the apical lung segments was necessary in 18 of 23 nodules. With the 1.1 mm flexible single-use cryoprobe, Jiang et al. reported that they could easily bend around sharp angles in the airway (e.g. distal left or right superior bronchus).

The large sample size, preserved-cellular architecture and presence of pathologically altered areas contrasted by normal tissue in the same sample facilitated histopathological diagnosis. These observations are supplemented by the latest results on the diagnostic advantages of cryobiopsy samples for next-generation sequencing. Thereby, cryobiopsy can have a deciding impact especially in molecular targeted therapy for non-small cell lung cancer (NSCLC).

The authors stress that further data is needed to confirm the safety and diagnostic value of the 1.1 mm flexible single-use cryoprobe.

Results and key findings

Selected lesion characteristics are depicted in Table 1. The median number of biopsies per lesion was three. Average sample size was 3.65 mm. The diagnostic yield was 82.61%. 19 out of 23 lesions were correctly diagnosed by peripheral cryobiopsy. Two adenocarcinomatous lesions were misdiagnosed as chronic inflammation, a further two provided unqualified samples.

No pneumothorax or severe hemorrhage occurred.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion size under 20 mm</td>
<td>14/23</td>
</tr>
<tr>
<td>Location in right or left upper lobe</td>
<td>18/23</td>
</tr>
<tr>
<td>Bronchus sign visible on HRCT</td>
<td>23/23</td>
</tr>
<tr>
<td>Invisible on fluoroscopy</td>
<td>14/23</td>
</tr>
</tbody>
</table>

Table 1: selected radiological features of the lesions

References


Products

The Erbe 1.1 mm flexible single-use cryoprobe was used (20402-402). The authors used freezing times between 3 and 5 seconds with ERBECRYO® 2.
Important information

We have prepared this document with care. Nonetheless, we cannot completely rule out errors in this document.

The information, recommendations and other data ("Information") contained in this document reflect our state of knowledge and the state of science and technology at the time of preparing the document. The information is of a general nature, non-binding and serves solely for general information purposes and does not represent instructions for use or notes on application.

The information and recommendations contained in this document do not constitute any legal obligations on Erbe Elektromedizin GmbH or their associated companies ("Erbe") or any other claims against Erbe. The information does not represent a guarantee or other quality statement; these require an express contractual arrangement with Erbe in individual cases.

Erbe shall not be liable for any type of damage resulting from following information given in this document, regardless of the legal reason for liability.

Every user of an Erbe product is responsible for checking the respective Erbe product for its properties as well as the suitability for the intended type of application or intended purpose in advance. The suitable type of application of the respective Erbe product is given by the user manual and the notes on use for the corresponding Erbe product. The user is obliged to check whether the existing user manual and the notes on use correspond with the status for the specific Erbe product. The devices may only be used according to the user manual and the notes on use.

The information on setting values, application sites, duration of application and the use of the respective Erbe product is based on the clinical experience of physicians independent from Erbe. They represent guidelines which need to be checked by the user for their suitability for the actual planned application. Depending on the circumstances of an actual application case, it may be necessary to deviate from the information provided. The user is responsible for checking this in each case when using an Erbe product. We wish to point out that science and technology is constantly subject to new developments arising from research and clinical experience. For this reason, it may be necessary for the user to deviate from the information provided in this document.

This document contains information about Erbe products which may possibly not be approved in a specific country. The user of the respective Erbe product is obliged to inform him/herself as to whether the Erbe product he/she is using is legally approved in his/her country and/or if legal requirements or restrictions for use possibly exist and to what extent.

This document is not intended for users in the USA.